What are peoples thoughts on the significance of these new cardio-oncology guidelines from the European Society of Cardiology (ESC) for our cardio-protection data?
A/Prof Aaron Sverdlov who recently met with Dr T seems to think it's a big deal for the field of cardio-oncology.
Seems like the presentation of these guidelines at the ESC2022 conference (which is happening now) has generated quite a bit of excitement - just go and look at what A/Prof Sverdlov is posting and retweeting regarding these guidelines.
I think this bodes well for the submission of data to a top journal that sheds some light on the cardio-protective potential of Zantrene, but has anyone read these guidelines closely?
I wonder are there any other golden nuggets of information within the guidelines that have implications for Zantrene or RAC - apart from the fact that there seems to be a huge amount of interest in this area.
If any of you are speaking to Dr T perhaps ask him for his thoughts. I bet he will be reading these guidelines with interest.
What are peoples thoughts on the significance of these new...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |